Medindia

X

SCOLR Pharma, Inc. First Quarter 2011 Financial Results

Wednesday, May 11, 2011 General News J E 4
Advertisement

SCOLR Pharma, Inc.

CONDENSED UNAUDITED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts and number of shares)

Three months ended

March 31,

2011

2010

(Restated)

Revenues

Licensing fees

$

—

$

25

Royalty income

66

141

Research and development

118

—

Total revenues

184

166

Operating expenses

Marketing and selling

125

59

Research and development

647

340

General and administrative

740

601

Total operating expenses

1,512

1,000

Loss from operations

(1,328)

(834)

Other income (expense)

Interest income

1

1

Unrealized gain (loss) on fair value of warrant

105

(218)

Total other income (expense)

106

(217)

Net loss

$

(1,222)

$

(1,051)

Net loss per share, basic and diluted

$

(0.02)

$

(0.02)

Shares used in computing basic and diluted net loss per share

49,816,073

43,140,968

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Claimsnet.com Reports Amended First Quarter 2011 R...
S
China Biologic Products Reports First Quarter 2011...